Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles

Journal of Controlled Release

Volumn 237, Issue , 2016, Pages 1-13

  Sugo, Tsukasa ^a   Terada, Michiko ^a   Oikawa, Tatsuo ^a   Miyata, Kenichi ^a   Nishimura, Satoshi ^a   Kenjo, Eriya ^a   Ogasawara Shimizu, Mari ^a   Makita, Yukimasa ^a   Imaichi, Sachiko ^a   Murata, Shumpei ^a   Otake, Kentaro ^a   Kikuchi, Kuniko ^a   Teratani, Mika ^a   Masuda, Yasushi ^a   Kamei, Takayuki ^a   Takagahara, Shuichi ^a   Ikeda, Shota ^a   Ohtaki, Tetsuya ^a   Matsumoto, Hirokazu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Antibody; CD71; Conjugate; Drug delivery system; Heart; Intramuscular injection; Myostatin; Peripheral artery disease (PAD); siRNA; Skeletal muscle; Targeting; Transferrin

Indexed keywords

ANTIBODIES; GENE THERAPY; GENES; GENETIC ENGINEERING; HEART; MAMMALS; MUSCLE; RNA;

CD71; CONJUGATE; DRUG DELIVERY SYSTEM; INTRAMUSCULAR INJECTIONS; MYOSTATIN; PERIPHERAL ARTERY DISEASE; SIRNA; SKELETAL MUSCLE; TARGETING; TRANSFERRIN;

DISEASES;

ANTIBODY CONJUGATE; CD71 ANTIBODY; MALEIMIDE; MYOSTATIN; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; CD71 ANTIGEN; LEUKOCYTE ANTIGEN; TRANSFERRIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; GASTROCNEMIUS MUSCLE; GENE SILENCING; HYPERTROPHY; IN VITRO STUDY; MALE; MOUSE; MUSCLE DISEASE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; RNA INTERFERENCE; RNAI THERAPEUTICS;

ANIMALS; ANTIGENS, CD; CELLS, CULTURED; FEMALE; IMMUNOCONJUGATES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOCARDIUM; MYOSTATIN; PERIPHERAL ARTERIAL DISEASE; RATS; RECEPTORS, TRANSFERRIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84977119106     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.06.036     Document Type: Article

References (52)

1. [1] Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S., Taneja, N., O'Shea, J., Shaikh, S., Zhang, L., van der Sluis, R.J., Jung, M.E., Akinc, A., Hutabarat, R., Kuchimanchi, S., Fitzgerald, K., Zimmermann, T., van Berkel, T.J., Maier, M.A., Rajeev, K.G., Manoharan, M., Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961.
2. [2] Wong, S.C., Klein, J.J., Hamilton, H.L., Chu, Q., Frey, C.L., Trubetskoy, V.S., Hegge, J., Wakefield, D., Rozema, D.B., Lewis, D.L., Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 22 (2012), 380–390.
3. [3] Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., Prabhala, H., Zhang, X., Attarwala, H., Hutabarat, R., Foster, D., Milstein, S., Charisse, K., Kuchimanchi, S., Maier, M.A., Nechev, L., Kandasamy, P., Kel'in, A.V., Nair, J.K., Rajeev, K.G., Manoharan, M., Meyers, R., Sorensen, B., Simon, A.R., Dargaud, Y., Negrier, C., Camire, R.M., Akinc, A., An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21 (2015), 492–497.
4. [4] Wittrup, A., Lieberman, J., Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16 (2015), 543–552.
5. [5] Huebers, H.A., Finch, C.A., The physiology of transferrin and transferrin receptors. Physiol. Rev. 67 (1987), 520–582.
6. [6] Gatter, K.C., Brown, G., Trowbridge, I.S., Woolston, R.E., Mason, D.Y., Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36 (1983), 539–545.
7. [7] Fishman, J.B., Rubin, J.B., Handrahan, J.V., Connor, J.R., Fine, R.E., Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18 (1987), 299–304.
8. [8] Friden, P.M., Walus, L.R., Musso, G.F., Taylor, M.A., Malfroy, B., Starzyk, R.M., Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 4771–4775.
9. [9] Yu, Y.J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J.M., Prabhu, S., Watts, R.J., Dennis, M.S., Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med., 3, 2011, 84ra44.
10. [10] Trowbridge, I.S., Transferrin receptor as a potential therapeutic target. Prog. Allergy 45 (1988), 121–146.
11. [11] Fava, R.A., Comeau, R.D., Woodworth, R.C., Specific membrane receptors for diferric-transferrin in cultured rat skeletal myocytes and chick-embryo cardiac myocytes. Biosci. Rep. 1 (1981), 377–385.
12. [12] Ponka, P., Lok, C.N., The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol. 31 (1999), 1111–1137.
13. [13] Cazzola, M., Bergamaschi, G., Dezza, L., Arosio, P., Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75 (1990), 1903–1919.
14. [14] Trowbridge, I.S., Omary, M.B., Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 3039–3043.
15. [15] Trowbridge, I.S., Domingo, D.L., Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294 (1981), 171–173.
16. [16] Qian, Z.M., Li, H., Sun, H., Ho, K., Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002), 561–587.
17. [17] Lai, B.T., Gao, J.P., Lanks, K.W., Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate. Cancer Chemother. Pharmacol. 41 (1998), 155–160.
18. [18] Wagner, E., Zenke, M., Cotten, M., Beug, H., Birnstiel, M.L., Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 3410–3414.
19. [19] Liang, K.W., Hoffman, E.P., Huang, L., Targeted delivery of plasmid DNA to myogenic cells via transferrin-conjugated peptide nucleic acid. Mol. Ther. 1 (2000), 236–243.
20. [20] Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K.F., Rait, A., Chang, E.H., Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21 (2013), 1096–1103.
21. [21] Bellocq, N.C., Pun, S.H., Jensen, G.S., Davis, M.E., Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 14 (2003), 1122–1132.
22. [22] Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998), 307–314.
23. [23] Bradley, L., Yaworsky, P.J., Walsh, F.S., Myostatin as a therapeutic target for musculoskeletal disease. Cell. Mol. Life Sci. 65 (2008), 2119–2124.
24. [24] McDermott, M.M., Hoff, F., Ferrucci, L., Pearce, W.H., Guralnik, J.M., Tian, L., Liu, K., Schneider, J.R., Sharma, L., Tan, J., Criqui, M.H., Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J. Am. Geriatr. Soc. 55 (2007), 400–406.
25. [25] Regensteiner, J.G., Wolfel, E.E., Brass, E.P., Carry, M.R., Ringel, S.P., Hargarten, M.E., Stamm, E.R., Hiatt, W.R., Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation 87 (1993), 413–421.
26. [26] Hooi, J.D., Kester, A.D., Stoffers, H.E., Overdijk, M.M., van Ree, J.W., Knottnerus, J.A., Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am. J. Epidemiol. 153 (2001), 666–672.
27. [27] Andrew, S.M., Titus, J.A., Fragmentation of immunoglobulin G. Curr. Protoc. Immunol., 2001 (Chapter 2, Unit 2.8).
28. [28] French, R.R., How to make bispecific antibodies. Methods Mol. Med. 40 (2000), 333–339.
29. [29] Lesley, J., Schulte, R., Woods, J., Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp. Cell Res. 182 (1989), 215–233.
30. [30] Temponi, M., Gold, A.M., Ferrone, S., Binding parameters and idiotypic profile of the whole immunoglobulin and Fab′ fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res. 52 (1992), 2497–2503.
31. [31] Futran, J., Kemp, J.D., Field, E.H., Vora, A., Ashman, R.F., Transferrin receptor synthesis is an early event in B cell activation. J. Immunol. 143 (1989), 787–792.
32. [32] Judd, W., Poodry, C.A., Strominger, J.L., Novel surface antigen expressed on dividing cells but absent from nondividing cells. J. Exp. Med. 152 (1980), 1430–1435.
33. [33] Iyer, U., Kadambi, V.J., Antibody drug conjugates — Trojan horses in the war on cancer. J. Pharmacol. Toxicol. Methods 64 (2011), 207–212.
34. [34] Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L., Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. 45 (2013), 2333–2347.
35. [35] Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P., Marasco, W.A., Lieberman, J., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23 (2005), 709–717.
36. [36] Ma, Y., Kowolik, C.M., Swiderski, P.M., Kortylewski, M., Yu, H., Horne, D.A., Jove, R., Caballero, O.L., Simpson, A.J., Lee, F.T., Pillay, V., Scott, A.M., Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA. ACS Chem. Biol. 16 (2011), 962–970.
37. [37] Cuellar, T.L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.F., Wen, X., Scales, S.J., Gesch, J., Davis, D., van Brabant Smith, A., Leake, D., Vandlen, R., Siebel, C.W., Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 43 (2015), 1189–1203.
38. [38] Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P., Peng, C.G., Kel'in, A.V., Kandasamy, P., Willoughby, J.L., Liebow, A., Querbes, W., Yucius, K., Nguyen, T., Milstein, S., Maier, M.A., Rajeev, K.G., Manoharan, M., siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10 (2015), 1181–1187.
39. [39] Kinouchi, N., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanimoto, Y., Moriyama, K., Noji, S., Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther. 15 (2008), 1126–1130.
40. [40] Wolff, J.A., Budker, V., The mechanism of naked DNA uptake and expression. Adv. Genet. 54 (2005), 3–20.
41. [41] Heemskerk, H., de Winter, C., van Kuik, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, G.J., de Kimpe, S., Ferlini, A., Aartsma-Rus, A., van Deutekom, J.C., Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18 (2010), 1210–1217.
42. [42] Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Blättler, W.A., Lambert, J.M., Chari, R.V., Lutz, R.J., Wong, W.L., Jacobson, F.S., Koeppen, H., Schwall, R.H., Kenkare-Mitra, S.R., Spencer, S.D., Sliwkowski, M.X., Targeting HER2-positive breast cancer with trastuzmab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68 (2008), 9280–9290.
43. [43] Barry, M.E., Pinto-González, D., Orson, F.M., McKenzie, G.J., Petry, G.R., Barry, M.A., Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum. Gene Ther. 10 (1999), 2461–2480.
44. [44] Greenberg, B., Gene therapy for heart failure. J. Cardiol. 66 (2015), 195–200.
45. [45] Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., Direct gene transfer into mouse muscle in vivo. Science 247 (1990), 1465–1468.
46. [46] Kawakami, E., Kinouchi, N., Adachi, T., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanaka, E., Noji, S., Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice. Develop. Growth Differ. 53 (2011), 48–54.
47. [47] Mori, H., Kawai, N., Kinouchi, N., Hichijo, N., Ishida, T., Kawakami, E., Noji, S., Tanaka, E., Effectiveness of cationic liposome-mediated local delivery of myostatin-targeting small interfering RNA in vivo. Develop. Growth Differ. 56 (2014), 223–232.
48. [48] LeBrasseur, N.K., Schelhorn, T.M., Bernardo, B.L., Cosgrove, P.G., Loria, P.M., Brown, T.A., Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 64A (2009), 940–948.
49. [49] Bernardo, B.L., Wachtmann, T.S., Cosgrove, P.G., Kuhn, M., Opsahl, A.C., Judkins, K.M., Freeman, T.B., Hadcock, J.R., LeBrasseur, N.K., Postnatal PPARδ activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS One, 5, 2010, e11307.
50. [50] Kirk, S., Oldham, J., Kambadur, R., Sharma, M., Dobbie, P., Bass, J., Myostatin regulation during skeletal muscle regeneration. J. Cell. Physiol. 184 (2000), 356–363.
51. [51] Whittemore, L.A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J.J., Jalenak, M., Kelley, P., Knight, A., Maylor, R., O'Hara, D., Pearson, A., Quazi, A., Ryerson, S., Tan, X.Y., Tomkinson, K.N., Veldman, G.M., Widom, A., Wright, J.F., Wudyka, S., Zhao, L., Wolfman, N.M., Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300 (2003), 965–971.
52. [52] Biesemann, N., Mendler, L., Wietelmann, A., Hermann, S., Schäfers, M., Krüger, M., Boettger, T., Borchardt, T., Braun, T., Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ. Res. 115 (2014), 296–310.